首页 | 本学科首页   官方微博 | 高级检索  
     


Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience
Authors:Barba Pere  Sampol Antonia  Calbacho María  Gonzalez José  Serrano Josefina  Martínez-Sánchez Pilar  Fernández Pascual  García-Boyero Raimundo  Bueno Javier  Ribera Josep Maria
Affiliation:Hematology Departments of Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. pebarba@vhebron.net
Abstract:
The present study reports the Spanish PETHEMA group experience in 31 heavily pretreated relapsed/refractory acute lymphoblastic leukemia (ALL) and lymphoma (LL) patients treated with clofarabine-based regimens. The complete remission (CR) rate was 31% (median CR duration of 3 months [range 2–28]) and the overall survival probability at 1 year was 10% (95%CI 4–16%). Responses were seen in B and T lineage diseases and in patients with adverse cytogenetics. Hematological and infectious grade >3 toxicities were found in 100 and 67% of the patients, respectively, with 7 (23%) treatment-related deaths. Other organ toxicities were infrequent. Clofarabine-based chemotherapy regimens might induce CRs in ALL and LL patients, but hematological toxicity and infections may limit their use in heavily pretreated patients.
Keywords:
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号